Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors

It remains a substantial challenge to targetedly deliver drug to both primary tumors and metastatic lesions employing a single nanoparticle delivery system. Here aiming at the receptor for hyaluronic acid mediated motility (RHAMM or CD168), a specific receptor for hyaluronic acid (HA), the bioreduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chenchen, Li, Cheng, Zhang, Peng, Wu, Wei, Jiang, Xiqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436523/
https://www.ncbi.nlm.nih.gov/pubmed/28529647
http://dx.doi.org/10.7150/thno.18340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5436523/
https://www.ncbi.nlm.nih.gov/pubmed/28529647
http://dx.doi.org/10.7150/thno.18340

Ejemplares similares